Description: MaxCyte, Inc. focuses on cell-based medicines. The Company's cell modification technology, Flow electroporation, is used for discovery, development and manufacture of small molecule, biologic and cell-based therapeutics. The Company's products include instruments, processing assemblies and insourcing services. Its instruments include systems, such as the MaxCyte STX, the MaxCyte VLX and the MaxCyte GT. The Company's MaxCyte GT Flow Transfection System, the MaxCyte STX Scalable Transfection System and the MaxCyte VLX Large Scale Transfection System enable the development and production of transfected cells for an array of applications. The Company offers a platform, which enables the engineering of a range of cells, including human primary cells. Its products are used in applications, including drug discovery, protein production and cell therapy. The Company offers messenger ribonucleic acid (mRNA) CAR T-cell based platform for immuno-oncology indications, including solid cancers.
Home Page: maxcyte.com
MXCT Technical Analysis
9713 Key West Avenue
Rockville,
MD
20850
United States
Phone:
301 944 1700
Officers
| Name | Title |
|---|---|
| Mr. Douglas Arthur Doerfler | Founder, Pres, CEO & Exec. Director |
| Mr. Ronald Evan Holtz CPA, Ph.D. | Chief Financial Officer |
| Dr. J. Stark Thompson Ph.D. | Consultant |
| Dr. Cenk Sumen | Chief Scientific Officer |
| Mr. Sean Menarguez | Director of Investor Relations |
| Mr. Maher Masoud | Exec. VP, Gen. Counsel & Sec. |
| Mr. Thomas Michael Ross | Exec. VP of Global Sales |
| Dr. James Brady Ph.D. | Sr. VP of Technical Applications & Customer Support |
| Dr. Sarah Haecker Meeks Ph.D. | Sr. VP of Bus. Devel. |
| Mr. James Lovgren | Sr. VP of Global Marketing |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.208 |
| Price-to-Sales TTM: | 10.9362 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 84 |